Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 27

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 27
---
. Our IT team works 24/7 and uses a combination of tools and technologies to help protect our stakeholder’s data. Our team members are responsible for complying with our data security standards and complete mandatory annual training to understand the behaviors and technical requirements necessary to keep sensitive information secure. We also offer ongoing education for team members to recognize and report suspicious activity. See Item 1C., Cybersecurity, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 for additional information regarding cybersecurity risk management strategy and governance.

<div align='center'>-17-</div>

EXECUTIVE OFFICERS Set forth below are the names, ages, offices held, tenure and certain biographical information of each of our executive officers as of April 18, 2025.

| Name                 |     | Age |     | Office(s)                               |     | Officer Since  |
| Brian M. Culley      |     |  53 |     | Chief Executive Officer and Director    |     | September 2018 |
| Jill A. Howe         |     |  49 |     | Chief Financial Officer                 |     | November 2022  |
| George A. Samuel III |     |  44 |     | General Counsel and Corporate Secretary |     | September 2021 |

Mr. Culley’s biographical information is included above with those of the other members of our Board. Jill A. Howe . Ms. Howe joined Lineage as Chief Financial Officer on November 14, 2022. Before joining Lineage, Ms. Howe most recently served as the Chief Financial Officer of DTx Pharma, Inc., a biotechnology company, a position she held from June 2021 through July 2022. Prior to joining DTx Pharma, from January 2018 to June 2021, Ms. Howe served as Vice President of Finance and Treasurer for Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company. Prior to Gossamer Bio, she served as Controller & Director of Finance of Amplyx Pharmaceuticals, Inc., a biopharmaceutical company, from March 2016 to December 2017. She previously held positions, including as Controller and Director of Finance, at Receptos, Inc., a biotechnology company, and at Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company. Since October 2021, Ms. Howe has served on the board of directors of Codagenix Inc